First Horizon Advisors Inc. Lowers Holdings in Sanofi (NASDAQ:SNY)

First Horizon Advisors Inc. trimmed its position in shares of Sanofi (NASDAQ:SNY) by 6.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,919 shares of the company’s stock after selling 456 shares during the period. First Horizon Advisors Inc.’s holdings in Sanofi were worth $334,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Sanofi by 434.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 50,583 shares of the company’s stock valued at $2,915,000 after buying an additional 41,117 shares during the period. Private Advisor Group LLC increased its stake in Sanofi by 2.6% during the third quarter. Private Advisor Group LLC now owns 52,338 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,339 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Sanofi during the third quarter worth about $7,038,000. Allworth Financial LP raised its position in shares of Sanofi by 7.5% during the 3rd quarter. Allworth Financial LP now owns 5,081 shares of the company’s stock worth $293,000 after purchasing an additional 355 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Sanofi by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,721 shares of the company’s stock valued at $676,000 after buying an additional 2,100 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 2.1 %

SNY stock opened at $54.89 on Wednesday. The company has a market cap of $139.30 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $51.22 and a two-hundred day moving average of $52.56.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SNY. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.